Neurocrine Biosciences earnings were $305.8M for the trailing 12 months ending Mar 31, 2025, with -19.6% growth year over year. The latest NBIX earnings report on Mar 31, 2025 announced Q1 2025 earnings of $7.9M, down 92.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NBIX reported annual earnings of $341.3M, with 36.7% growth. The next NBIX earnings date is Jul 30, 2025.
NBIX past earnings growth
How has NBIX's earnings growth performed historically?
Neurocrine Biosciences Earnings Reports & History FAQ
What were Neurocrine Biosciences's earnings last quarter?
On NBIX's earnings call on Invalid Date, Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 2025 earnings per share (EPS) of $0.08, up 81.4% year over year. Total NBIX earnings for the quarter were $7.90 million. In the same quarter last year, Neurocrine Biosciences's earnings per share (EPS) was $0.43.
The next NBIX earnings call is Invalid Date. Add NBIX to your watchlist to be reminded of Neurocrine Biosciences's next earnings date.
Is Neurocrine Biosciences profitable or losing money?
As of the last Neurocrine Biosciences earnings report, Neurocrine Biosciences is currently profitable. Neurocrine Biosciences's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $305.80 million, a 17.28% decrease year over year.
What was NBIX's earnings growth in the past year?
As of Neurocrine Biosciences's earnings date in Invalid Date, Neurocrine Biosciences's earnings has grown -19.63% year over year. This is 20.87 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 1.24%. NBIX earnings in the past year totalled $305.80 million.
What are Neurocrine Biosciences's earnings expectations?
The current EPS estimate for Neurocrine Biosciences's earnings report in Invalid Date is $0.98.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.